C677T and A1298C methylenetetrahydrofolate reductase polymorphisms and breast cancer susceptibility among Latinos: a meta-analysis
- 148 Downloads
Previous meta-analyses have shown an ethnic dependency of the C677T and the A1298C methylenetetrahydrofolate reductase (MTHFR) polymorphisms, with no focus on the Latino population. For Latinos, many studies have examined these polymorphisms and breast cancer susceptibility, yielding no concise result. Therefore, we undertook this meta-analysis to determine the effect these polymorphisms have on breast cancer risk for Latinos.
PubMed, EBSCO, LILACS, Scopus, and Latin American-specific databases were searched for studies exploring the association between the MTHFR polymorphisms and breast cancer susceptibility in Latinos until January 2019. Genotype distributions were extracted and, depending on the level heterogeneity determined by the ψ2-based Q test and the I2 test, fixed-effects or random-effects models were used to calculate pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) for the heterozygous, homozygous, dominant, recessive, and allelic genetic models. No publication bias was detected by the Begg–Mazumdar’s test and Egger’s test.
Of the 280 retrieved publications, 9 studies were included: 9 for the C677T polymorphism and 5 for the A1298C polymorphism. For the C677T polymorphism, there was an elevated risk for the homozygous (OR 1.42, 95% CI 1.05–1.92), the dominant (OR 1.16, 95% CI 1.02–1.31), the recessive (OR 1.33, 95% CI 1.01–1.75), and the allelic model (OR 1.17, 95% CI 1.03–1.33, p < 0.01). No association between the A1298C polymorphism and the risk to develop breast cancer was determined.
The results indicated that, for Latinos, the C677T polymorphism is associated with a significant risk for developing breast cancer, whereas the A1289C polymorphism does not.
KeywordsMTHFR Mutation Carcinogenesis Latin America
The authors would like to express their gratitude to Mtro. Ricardo Villegas Tovar, Coordinator of Scientific Production and International Visibility, BUAP.
This study was supported by grants from Programa para el Desarrollo Profesional Docente (to CA-160 FACMED) and Vicerrectorıa de Investigacion, Benemerita Universidad Autonoma de Puebla, Mexico (to TORE-SAL18-G, PEFR-SAL18-G, and GOMM-SAL18-I).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
- 1.Cancer Key Facts. Publisher WHO Geneva, Headquarters in Geneva. 2018. http://www.unesco.org/new/en/unesco/worldwide/latin-america-and-the-caribbean/. Accessed 11 May 2018.
- 2.Partanen T, Monge P, Wesseling C. Causes and prevention of occupational cancer. Acta Médica Costarricense. 2009;51(4):195–205.Google Scholar
- 18.Zara-Lopes T, Gimenez-Martins AP, Nascimento-Filho CH, Castanhole-Nunes MM, Galbiatti-Dias AL, Padovani-Junior JA, et al. Role of MTHFR C677T and MTR A2756G polymorphisms in thyroid and breast cancer development. Genet Mol Res. 2016;15(2):;gmr8222. https://doi.org/10.4238/gmr.15028222.CrossRefGoogle Scholar
- 20.Miller JJ. The inverse of the Freeman–Tukey double arcsine transformation. Am Stat. 1978;32(4):138-.Google Scholar
- 23.Le Marchand L, Haiman CA, Wilkens LR, Kolonel LN, Henderson BE. MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomark Prev. 2004;13(12):2071–7.Google Scholar
- 24.Lopez-Cortes A, Echeverria C, Ona-Cisneros F, Sanchez ME, Herrera C, Cabrera-Andrade A, et al. Breast cancer risk associated with gene expression and genotype polymorphisms of the folate-metabolizing MTHFR gene: a case–control study in a high altitude Ecuadorian mestizo population. Tum Biol J Int Soc Oncodev Biol Med. 2015;36(8):6451–61.CrossRefGoogle Scholar
- 40.Platek ME, Shields PG, Marian C, McCann SE, Bonner MR, Nie J, et al. Alcohol consumption and genetic variation in methylenetetrahydrofolate reductase and 5-methyltetrahydrofolate-homocysteine methyltransferase in relation to breast cancer risk. Cancer Epidemiol Biomark Prev. 2009;18(9):2453–9.CrossRefGoogle Scholar